IDEV - ETF AI Analysis

Top Page

iShares Core MSCI International Developed Markets ETF (IDEV)

Rating:66Neutral

Price Target:―

IDEV’s rating suggests it is a solid, broadly diversified international developed-markets ETF, supported by several high-quality leaders. Strong holdings like AstraZeneca, HSBC, Novartis, and Toyota, all backed by robust financial performance and positive outlooks, help lift the fund’s overall quality, while names such as SAP and Nestlé, which face technical or valuation challenges, may modestly weigh on the rating. The main risk is that many top positions are large, mature companies in similar developed markets, so the fund is still exposed to broad economic and valuation risks in those regions.

Positive Factors

Low Expense Ratio

The fund charges a very low fee, which helps investors keep more of their returns over time.

Broad International Diversification

Holdings spread across many developed countries like Japan, the UK, Europe, Canada, and others help reduce the impact of problems in any single market.

Healthy Size and Recent Performance

The ETF has a large asset base and has shown steady gains over the past month, three months, and year-to-date, suggesting it is widely used and has been performing reasonably well.

Negative Factors

Heavy Tilt to Financials and Industrials

A large share of the portfolio is in financial and industrial companies, which can hurt returns if these sectors struggle.

Mixed Results Among Top Holdings

While some leading positions like ASML, Roche, Siemens, Toyota, and others have been strong, several other major holdings have been weak, which can drag on overall performance.

Limited Exposure to High-Growth Tech

Technology makes up a relatively small part of the portfolio, so the fund may benefit less if global tech stocks outperform.

IDEV vs. SPDR S&P 500 ETF (SPY)

AUM28.32B

RegionDeveloped Markets

Expense Ratio0.04%

Beta0.71

IssueriShares

Inception DateMar 21, 2017

Dividend Yield3.14%

Asset ClassEquity

Index TrackedMSCI World ex USA IMI

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,042,901

30 Day Avg. Volume2,268,820

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

100.76

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2220

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IDEV Summary

IDEV is an ETF that tracks the MSCI World ex USA IMI index, giving you broad exposure to stocks in developed countries outside the U.S. and Canada. It owns thousands of companies across many sectors and regions, including well-known names like Nestlé, Toyota, and ASML. Someone might invest in IDEV to diversify beyond the U.S. market and tap into long-term growth in Europe, Japan, and other developed economies, all in a single fund. A key risk is that international stock prices can go up and down with global markets and currency swings.

How much will it cost me?The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.

What would affect this ETF?Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.

IDEV Top 10 Holdings

IDEV’s story is driven by a handful of global heavyweights, with Europe and Japan doing much of the lifting. Chip-equipment star ASML is rising and acting like a key engine for the fund, while health-care leaders Roche and Novartis are steadily adding support. Big banks like HSBC and Royal Bank of Canada reflect the ETF’s tilt toward financials, though their impact is more measured. On the softer side, consumer giant Nestlé and software player SAP have been lagging, slightly braking an otherwise broadly diversified, developed-markets ride outside the U.S.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	1.87%	$527.85M	€450.67B	61.10%	76 Outperform
ROG	Roche Holding AG	1.12%	$317.38M	CHF287.79B	42.71%	73 Outperform
AZN	AstraZeneca	1.08%	$305.52M	£231.12B	29.12%	80 Outperform
NOVN	Novartis AG	1.04%	$295.31M	CHF235.62B	31.22%	80 Outperform
HSBA	HSBC Holdings	1.01%	$286.90M	£217.54B	42.42%	80 Outperform
NESN	Nestlé SA	0.90%	$254.77M	CHF200.67B	13.36%	71 Outperform
RY	Royal Bank Of Canada	0.81%	$228.84M	$237.03B	42.26%	75 Outperform
SIE	Siemens	0.79%	$224.77M	€200.53B	11.12%	74 Outperform
7203	Toyota Motor	0.78%	$221.71M	¥48.29T	34.78%	80 Outperform
SHEL	Shell (UK)	0.77%	$218.76M	£163.31B	7.42%	73 Outperform

IDEV Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

84.49

Positive

100DMA

81.81

Positive

200DMA

78.12

Positive

Market Momentum

MACD

1.43

Negative

RSI

65.41

Neutral

STOCH

82.95

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 87.21, equal to the 50-day MA of 84.49, and equal to the 200-day MA of 78.12, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 65.41 is Neutral, neither overbought nor oversold. The STOCH value of 82.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDEV.

IDEV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IDEV	―	―	$28.32B	0.04%	―
VEA	―	―	$214.85B	0.03%	―
SCHF	―	―	$61.05B	0.03%	―
SPDW	―	―	$38.07B	0.03%	―
DFAI	―	―	$14.60B	0.18%	―
AVDE	―	―	$14.18B	0.23%	―

Performance Comparison

IDEV

iShares Core MSCI International Developed Markets ETF

89.38

21.95

32.55%

VEA

Vanguard FTSE Developed Markets ETF

―

SCHF

Schwab International Equity ETF

―

SPDW

SPDR Portfolio Developed World ex-US ETF

―

DFAI

Dimensional International Core Equity Market ETF

―

AVDE

Avantis International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents